

SUPPLEMENTAL MATERIAL


Role of Factor Xa-Independent Pathway and Anticoagulant therapies in Cancer-related Stroke

Hyung Jun Kim, M.D., Jong-Won Chung, M.D., Ph.D., Oh Young Bang, M.D., Ph.D., Yun Jeong Lim, R.N., Jaechun Hwang, M.D. Woo-Keun Seo, M.D., Ph.D., Gyeong-Moon Kim, M.D., Ph.D., Hee-Jin Kim, M.D., Ph.D., Myung-Ju Ahn, M.D., Ph.D.

Table S1. Laboratory findings associated with recurrence of cancer stroke and treatment-related changes.

	Situation 1	Situation 2	<i>P</i>
Recurrence of cancer stroke	Stable	Recurrence	
D-dimer, µg/mL (n=10)	8.80±7.31	28.11±21.22	0.002
Factor Xa, % (n=9)	69.11±9.96	62.33±18.32	0.164
cfDNA, ng/ml (n=6)	51.56±9.94	65.70±13.49	0.022
Cancer stroke	Enoxaparin		
	Pre-treat	Post-treat	
D-dimer, µg/mL (n=32)	16.05±13.28	8.58±12.26	0.011
Factor Xa, % (n=28)	71.35±25.15	71.92±19.56	0.858
cfDNA, ng/ml (n=15)	53.69±18.86	52.98±11.41	0.495
Cancer stroke	Edoxaban		
	Pre-treat	Post-treat	
D-dimer, µg/mL (n=12)	16.68±10.48	13.08±9.43	0.071
Factor Xa, % (n=12)	77.44±15.49	68.94±14.61	0.019
cfDNA, ng/ml (n=9)	56.73±6.54	71.38±12.30	<0.001
AF stroke	Factor Xa inhibitor		
	Pre-treat	Post-treat	
D-dimer, µg/mL (n=16)	1.53±1.76	0.37±0.16	0.009
Factor Xa, % (n=35)	81.92±15.10	75.71±14.21	0.002
cfDNA, ng/ml (n=15)	41.97±7.75	38.05±4.04	0.096

Figure S1. An example case showing D-dimer, factor Xa activity, and cell free DNA levels changes between the occurrence and recurrence of cancer stroke.



A 65-year-old female patient with pancreatic head cancer and liver metastasis was referred to a neurologist due to sudden disorientation while hospitalized for chemotherapy. After 3 days of receiving 1 mg/kg enoxaparin (twice a day), D-dimer level decreased and the disorientation improved, so she was transferred to edoxaban. After 3 days of receiving edoxaban, worsening of disorientation and right-hand weakness occurred, and stroke recurrence was confirmed by the diffusion-weighted image.